Table 2.
Effect of Combination Therapy on Growth of HCC1806-RR Tumors In Vivo.
| Treatment | N | Drug Dose (mg/kg) | Mean Tumor Volume (mm3) | % Inhibition of Control | TGD* vs Control | % CR† | P value vs | |
| Control | ABX | |||||||
| Control | 7 | - | 1799 ± 169 | - | - | 0 | - | - |
| Bev‡ | 8 | 4 | 2126 ± 297 | 0 | 0 | 0 | NS‡ | - |
| ABX‡ | 8 | 10 | 180 ± 55 | 90 | >28 | 0 | <.001 | - |
| ABX + Bev | 8 | 10/4 | 0 | 100 | >28 | 50 | <.001 | .024 |
*
Tumor growth delay (TGD) is defined as number of days that delayed the mean tumor volume per group reaching 1000 mm3 as compared with the saline-treated control groups.
†
CR was defined as the absence of palpable tumor at the original tumor injection site at the end of the experiment.
‡
Bev, ABX, and ABX + Bev denote treatment with bevacizumab, nab-paclitaxel, and combination of the two drugs, respectively. NS stands for not significant.